1 / 8

Dapagliflozin Helps To Minimize Heart Failure Rates

It is well established that patients with type-2 diabetes have a higher risk of cardiovascular complications. An exploratory analysis of the DAPA-HF trial data reveals that dapagliflozin treatment is associated with a significant reduction in the risk of cardiovascular death.<br>

pinnaclelifescience
Download Presentation

Dapagliflozin Helps To Minimize Heart Failure Rates

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dapagliflozin Helps To Minimize Heart Failure Rates

  2. About Pinnacle Lifescience • Pinnacle Life Science is a 100% subsidiary of India’s most trusted pharmaceutical company Aarti Drugs Ltd (ADL) and forms part of $ 1.5 billion conglomerate of the esteemed Aarti Group of Industries. • With 35 years of healthcare commitment through Aarti Drugs, Pinnacle has made its presence in nearly 90+ countries. Treading carefully on the path of efficient healthcare, the state-of-the-art manufacturing facility is designed to produce formulations that meet international quality standards and stringent regulatory compliances to trade beyond borders. • With significant expansion in R&D, Manufacturing & Marketing capabilities, we are poised for an accelerated growth.

  3. Does Dapagliflozin Reduce The Risk Of Cardiovascular Death? • It is well established that patients with type-2 diabetes have a higher risk of cardiovascular complications. An exploratory analysis of the DAPA-HF trial data reveals that dapagliflozin treatment is associated with a significant reduction in the risk of cardiovascular death. • The increased benefits of dapagliflozin have put the dapagliflozin manufacturer in India at the forefront. While cardiovascular disease remains the leading cause of death, the approval of multiple novel glucose-lowering agents has provided clinicians with various treatment options. Type 2 diabetes mellitus (T2DM) is a global epidemic that affects over 450 million adults and is increasing healthcare expenditures.

  4. Does Dapagliflozin Reduce The Risk Of Cardiovascular Death? • Multiple cardiovascular outcome trials (CVOTs) conduct to clarify the effect of novel anti-diabetic agents on significant cardiovascular endpoints. While improved glycemic control is associated with beneficial effects on microvascular outcomes, the result on cardiovascular endpoints has no conclusion. • As a result, pharma contract manufacturers in India recommend that the selection of an anti-diabetic medication should not solely be based on the possibility of improved glycemic control but also on the capability of antihyperglycemic medications to provide cardiovascular benefits. • The study included people who had diabetes and people who had heart failure that was getting worse and were either treated in a hospital or an outpatient setting. Additionally, individuals included had echocardiogram (ECG) values at enrollment that were higher than or equal to 40%.

  5. Does Dapagliflozin Reduce The Risk Of Cardiovascular Death? • Effects of Dapagliflozin on Men and Women • Due to sex-related differences in pharmacy kinetics and dynamics, women respond differently to specific treatments than men. • Other studies have shown that cardiac resynchronization therapy reduces women’s risk of all-cause death, cardiovascular death, death or heart failure hospitalization, ventricular arrhythmias or sudden cardiac death more than men do. Such studies help top CDMO companies in India to manufacture more affordable medications for the masses.

  6. Does Dapagliflozin Reduce The Risk Of Cardiovascular Death? • Dapagliflozin manufacturers in India say that the drug reduced the primary outcome of a worsening HF event or cardiovascular death in men and women in this prespecified subgroup analysis of DAPA-HF. Additionally, regardless of sex, dapagliflozin consistently outperformed other clinical endpoints, such as first- and recurrent HF hospitalization, cardiovascular death, and all-cause death. In an optimally treated cohort of patients with HFrEF, these data demonstrate the clinically significant benefits of dapagliflozin, regardless of sex. • Women and men experienced similar effects of dapagliflozin on eGFR, body weight, systolic blood pressure, and hematocrit. In this regard, it is crucial to note that women had comparable clinical benefits despite having worse kidney function than men at baseline, which should have reduced glucosuria and diuresis.

  7. Does Dapagliflozin Reduce The Risk Of Cardiovascular Death? • Dapagliflozin improves both men’s and women’s symptoms, physical function, and health-related quality of life and decreases the risk of worsening HF events, cardiovascular death, and all-cause death. • The rewarding research results prove that dapagliflozin is a miracle medicine that improves morbidity and reduces the risk of death in cases of heart failure. • The studies may produce positive outcomes if they have more supporting data. Clinics are always looking for a dependable producer of pharmaceuticals. Pinnacle, a pharma contract manufacturer in India, is ready to provide something meaningful yet beneficial for the masses. We are always looking for ways to make a healthier world.

  8. Contact Us Address: Mahendra Industrial Estate, Ground Floor, Plot No. 109D, Road No 29, Sion(E) Mumbai-400022, India. Phone No: +91 (22) – 24019025 Email: export.pinnacle@aartidrugs.com Site: www.pinnaclelifescience.com

More Related